Skip to main content
Premium Trial:

Request an Annual Quote

DiaCarta Raises $8M in Series A Round

NEW YORK (GenomeWeb) – DiaCarta today announced it raised $8 million in a Series A financing round. 

Proceeds will go toward commercialization of its products and the expansion of its portfolio, it said, adding the financing came from BioVeda China Fund. In conjunction with BVCF's financing, Weixin Xu, a principal at the venture capital fund, will join DiaCarta's board.

Based in Hayward, Calif., DiaCarta calls itself a translational genomics and molecular diagnostics firm that has CE-IVD assays for detecting EGFR, KRAS, NRAS, BRAF, PIK3CA, and JAK-2 mutations. Its QClamp mutation detection assays use a novel xeno-nucleic acid clamping technology to suppress amplification of wild-type DNA, enabling researchers to selectively amplify mutant DNA with real-time PCR.

According to the company, the technology can detect mutant DNA present at less than .1 percent, and its sensitivity and specificity make QClamp superior to next-generation sequencing and droplet digital PCR.

In addition to CE-IVD marking, its assays have been cleared by the Chinese Food and Drug Administration, DiaCarta said.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.